Qiangji Pharmaceutical

Qiangji Pharmaceutical is a clinical-stage biotechnology company based in Shanghai, China, specializing in the discovery and development of innovative small molecule drugs. The company focuses on the ubiquitin-proteasome system, specifically targeting deubiquitinating enzymes (DUBs) to address unmet needs in oncology. Its lead program, QJ-001, is a highly selective inhibitor of Ubiquitin-specific protease 7 (USP7) currently being evaluated in Phase 1 clinical trials for advanced solid tumors. Qiangji leverages a proprietary discovery platform that combines structural biology, medicinal chemistry, and deep biological insights. The company is backed by leading venture capital firms and aims to develop first-in-class or best-in-class therapies for cancer patients worldwide.